Answers are grounded in this paper and cite their sources.
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is being used in oncology as a noninvasive method for measuring properties of the tumor microvasculature. There is potential for DCE-MRI to be used as an imaging biomarker to measure antiangiogenic effects of cancer treatments. This article reviews the general methodology for performing DCE-MRI and discusses existing data and challenges to applying DCE-MRI for treatment response assessment in clinical trials.
No takes yet. Share an insight, caveat, or question.
Nola M. Hylton (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: